Here are relevant reports on : North-American Drug Delivery Technologies Market
-
Europe Pharmaceutical Drug Delivery Market By Route of Administration [Oral (Tablet, Capsule), Injector, Topical (Cream, Transdermal Patch), Transmucosal, Nasal], Application [Cancer, Diabetes], Care Setting [Hospital, Homecare]-Forecast to 2031
Europe Pharmaceutical Drug Delivery market, valued at US$501.6 million in 2025, stood at US$519.6 million in 2026 and is projected to advance at a resilient CAGR of 6.2% from 2026 to 2031, culminating in a forecasted valuation of US$703.2 million by the end of the period. The major trends in this market are self-administration, technology-driven drug delivery, sustainable drug delivery, and drug device combinations.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
US Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) - Forecast to 2031
The US injectable drug delivery market is expected to grow from USD 285.81 billion in 2025 to USD 465.15 billion by 2031, at a compound annual growth rate (CAGR) of 8.5% during the forecast period. The Key Players BD (US), West Pharmaceutical Services, Inc. (US), Cardinal Health (US), Baxter (US), B. Braun SE (Germany), Pfizer Inc. (US), Johnson & Johnson (US), Merck & Co., Inc. (US), Eli Lilly and Company (US), and AbbVie Inc. (US).
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Nasal Drug Delivery Technology Market by Dosage Form (Nasal Drops, Sprays, Powder, Gel), System (Multidose, Unit Dose, BI-Dose), Therapeutic Applications (Rhinitis, Congestion, Vaccinations), End User (Hospitals, Homecare) - Global Forecast to 2021
The global nasal drug delivery technology market is projected to grow at a CAGR of 6.5%. Key players in the nasal drug delivery technology market include Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Johnson& Johnson Services, Inc. (U.S.), Pfizer, Inc. (U.S.), AstraZeneca Plc.(U.S.), Aptar Group (U.S.), and GlaxoSmithKline plc (U.K.).
- Published: January 2017
- Price: $ 4950
- TOC Available:
-
Global Albumin Market, by Product (Human Serum Albumin, Bovine Albumin, Recombinant Serum Albumin) by Application (Therapeutic, Drug Delivery, Culture Media, Vaccine Ingredient) by Region - Forecast to 2022
The global albumin market is projected to grow at a CAGR of around 6% during the forecast period (2017-2022). Factors such as the high demand of albumin in R&D activities, rising non-therapeutic application of albumin, development of plant based albumin, rising production of immunoglobulins, and rise in plasma collection are driving the market. However, the stringent regulations, limited reimbursement, and irrational uses and adverse effects associated with albumin are the factors restraining the growth of this market.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023
The transdermal drug delivery system market is projected to reach USD 7.1 billion by 2023, growing at a CAGR of 4.5%. The growth of this market is primarily driven by factors such as the increase in the prevalence of chronic diseases and technological advancements in transdermal drug delivery systems. The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).
- Published: January 2019
- Price: $ 4950
- TOC Available:
-
Nanotechnology Drug Delivery System Market by Type, End-User, Industry, Application and Region - Global Forecast to 2030
The market for drug delivery systems that use nanotechnology to improve the delivery and targeting of medicinal medicines to certain areas within the body is referred to as the nanotechnology drug delivery system market. Drug delivery techniques based on nanotechnology solve problems with conventional approaches, such as low solubility, restricted bioavailability, and lack of specificity, by utilising nanoscale materials and structures.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Live Cell Encapsulation Market by Technique (Dripping (Simple, Electrostatic), Coaxial Airflow, Liquid Jet), Polymer (Alginate, Chitosan, Silica, Cellulose Sulfate), Application (Probiotics, Transplant, Drug Delivery, Research) - Forecast to 2024
The live cell encapsulation market is projected to grow to USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2% during the forecast period. Growth in the live cell encapsulation market is primarily driven by factors such as the increasing public-private investments to support product development, increasing research to establish the clinical efficacy of cell encapsulation technologies, and rising public awareness related to the clinical role of encapsulated cells in disease management. BioTime, Inc. (US), Viacyte, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top three players in the live cell encapsulation market. Other prominent players operating in this market include Sigilon Therapeutics, Inc. (US), Evonik Industries (Germany), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), and Sernova Corporation (Canada), among others. Furthermore, the key players in the developmental pipeline products in this market include Neurotech Pharmaceuticals, Inc. (US), Gloriana Therapeutics (US), Kadimastem (Israel), Beta-O2 Technologies, Inc. (Israel), Defymed (France), and Altucell, Inc. (US), among others.
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Bioresorbable Polymers Market by Type (Polylactic Acid (PLA), Polyglycolic Acid (PGA), Polylactic-co-glycolic acid (PLGA), Polycaprolactone) PCL), Application (Orthopedic Devices, Drug Delivery), and Region - Global Forecast to 2029
The bioresorbable polymers market is expected to grow from USD 500.0 million in 2024 to USD 867.2 million by 2029, at a CAGR of 11.6% during the forecast period. The key players profiled in the report include Corbion (Netherlands), Evonik Industries AG (Germany), Foster Corporation (US), KLS Martin Group (Germany), DSM Biomedical (US), Ashland Global Holdings Inc. (US), Zeus Company LLC (US), Seqens (France), Reva Medical, LLC (US), and Poly-Med Incorporated (US).
- Published: November 2024
- Price: $ 4950
- TOC Available:
-
Europe Injectable Drug Delivery Market by Product (Device, Self Injection, Formulation, Solution, Emulsions), Formulation Packaging (Ampoules, Bottles), Therapeutic Application (Obesity, Diabetes, Cancer, Psoriasis), Usage Pattern - Forecast to 2031
The Europe injectable drug delivery market is projected to reach USD 259.49 billion by 2031 from USD 178.87 billion in 2026, at a CAGR of 7.7% during the forecast period. The prominent players in the injectable drug delivery market in Europe are BD (US), Baxter (US), Gerresheimer AG (Germany), SCHOTT Pharma (Germany), West Pharmaceutical Services, Inc. (US), Pfizer Inc. (US), Sanofi (France), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson (US), among others.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Injectable Drug Delivery Market by Product (Device, Autoinjectors, Formulation, Suspensions, Nanoparticles), Site of Administration (Dermal, Organ), Formulation Packaging (Ampoules, Vials), Usage Pattern (Curative, Immunization) - Forecast to 2031
The Asia Pacific injectable drug delivery market is projected to reach USD 282.22 billion by 2031 from USD 176.96 billion in 2026, at a CAGR of 9.8% during the forecast period. The prominent players in the Asia Pacific injectable drug delivery market are BD (US), Terumo Corporation (Japan), Nipro (Japan), Hindustan Syringes & Medical Devices Ltd (India), B. Braun SE (Germany), Pfizer Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Novo Nordisk A/S (Denmark), and Novartis AG (Switzerland), among others.
- Published: January 2026
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
